Conv. Plasma
Nigella Sativa
Peg.. Lambda

All famotidine studies
Meta analysis
Home COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study

Momtazmanesh et al., Journal of Psychosomatic Research, doi:10.1016/j.jpsychores.2023.111389, IRCT20090117001556N138
May 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 50 recovered COVID-19 patients evaluating the efficacy of famotidine for improving cognitive impairment, depression and anxiety. At 6 and 12 weeks, the famotidine group had significantly greater improvements in MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) scores compared to placebo, indicating better cognitive function. The famotidine group also had slightly greater reductions in HAM-D (Hamilton Depression Rating Scale) and significant reductions in HAM-A (Hamilton Anxiety Rating Scale), suggesting improvements in depression and anxiety symptoms. There were no differences in adverse events between groups. In summary, this double-blind RCT found that famotidine significantly improved cognitive impairment and anxiety in patients recovering from COVID-19, with a minor improvement for depression, without statistical significance. The treatment was well-tolerated.
Momtazmanesh et al., 31 May 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, survey, 11 authors, study period September 2021 - July 2022, trial IRCT20090117001556N138.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFamotidineAll
Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study
Sara Momtazmanesh, Sahar Ansari, Zahra Izadi, Parnian Shobeiri, Venus Vatankhah, Arash Seifi, Fereshteh Ghiasvand, Mahboobeh Bahrami, Mohammdreza Salehi, Ahmad Ali Noorbala, Shahin Akhondzadeh
Journal of Psychosomatic Research, doi:10.1016/j.jpsychores.2023.111389
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Declaration of Competing Interest No conflict of interest exists for any of the authors associated with the manuscript.
Ahmadi, Ebrahimzadeh, Ahmad-Ashrafi, Karami, Mahdavi et al., Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists, Fundam. Clin. Pharmacol
Aiello, Fiabane, Manera, Radici, Grossi et al., Screening for cognitive sequelae of SARS-CoV-2 infection: a comparison between the Mini-mental state examination (MMSE) and the Montreal cognitive assessment (MoCA), Neurol. Sci
Akhondzadeh, Ahmadi-Abhari, Assadi, Shabestari, Kashani et al., Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal, J. Clin. Pharm. Ther
Alemanno, Houdayer, Parma, Spina, Del et al., COVID-19 cognitive deficits after respiratory assistance in the subacute phase: a COVID-rehabilitation unit experience, PLoS One
Alper, Case report: famotidine for neuropsychiatric symptoms in COVID-19, Front. Med
Anthony, Breitner, Zandi, Meyer, Jurasova et al., Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study, Neurology
Berg, Palm, Playing catch with long COVID -Understanding a new disease, Lancet Reg. Health -Europe
Boustani, Hall, Lane, Aljadhey, Gao et al., The association between cognition and histamine-2 receptor antagonists in African Americans, J. Am. Geriatr. Soc
Breitner, Welsh, Helms, Gaskell, Gau et al., Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs, Neurobiol. Aging
Carfì, Bernabei, Landi, Group ftGAC-P-ACS: persistent symptoms in patients after acute COVID-19, JAMA
Ceban, Ling, Lui, Lee, Gill et al., Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis, Brain Behav. Immun
Chazot, Johnston, Mcauley, Bonner, Histamine and delirium: current opinion, Front. Pharmacol
Cheung, Hung, Leung, Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study, Gastroenterology
Chiu, Shen, Lo, Chiu, Chen et al., Effect of famotidine on hospitalized patients with COVID-19: a systematic review and meta-analysis, PLoS One
Christina, Sandeep, Xiang, Richard, Nicole et al., Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial, Gut
Crum, Anthony, Bassett, Folstein, Population-based norms for the Mini-mental state examination by age and educational level, JAMA
Dannon, Lepkifker, Iancu, Ziv, Horesh et al., Famotidine: a supplemental drug for the treatment of schizophrenia, Eur. Psychiatr
Desforges, Le Coupanec, Stodola, Meessen-Pinard, Talbot, Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis, Virus Res
Deutsch, Rosse, Kendrick, Fay-Mccarthy, Collins, Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data, Clin. Neuropharmacol
Fernández-Castañeda, Lu, Geraghty, Song, Lee et al., Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation, Cell
Freedberg, Conigliaro, Wang, Tracey, Callahan et al., Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study, Gastroenterology
Fujii, Tanimukai, Kashiwagi, Comparison and analysis of delirium induced by histamine H2 receptor antagonists and proton pump inhibitors in cancer patients, Case Rep. Oncol
Ghosh, Chatterjee, Dubey, Lavie, Famotidine against SARS-CoV2: a hope or hype?
Gokhan, Feyza, Famotidine improved schizophrenia-like behaviors in acute ketamine model of schizophrenia in rats, PBS
Gray, Walker, Dublin, Haneuse, Crane et al., Histamine-2 receptor antagonist use and incident dementia in an older cohort, J. Am. Geriatr. Soc
Hanlon, Landerman, Artz, Gray, Fillenbaum et al., Histamine2 receptor antagonist use and decline in cognitive function among community dwelling elderly, Pharmacoepidemiol. Drug Saf
Iwasaki, Yang, The potential danger of suboptimal antibody responses in COVID-19, Nat. Rev. Immunol
Jafarinia, Afarideh, Tafakhori, Arbabi, Ghajar et al., Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial, J. Affect. Disord
Janowitz, Gablenz, Pattinson, Wang, Conigliaro et al., Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut
Kagevi, Thorhallsson, Wahlby, CSF concentrations of famotidine, Br. J. Clin. Pharmacol
Kamal, Khan, Sharma, Imam, Howden, Lack of consistent associations between pharmacologic gastric acid suppression and adverse outcomes in patients with coronavirus disease 2019: meta-analysis of observational studies, Gastroenterology
Kashani, Eslatmanesh, Saedi, Niroomand, Ebrahimi et al., Comparison of saffron versus fluoxetine in treatment of mild to moderate postpartum depression: a double-blind, randomized clinical trial, Pharmacopsychiatry
Kishi, Iwata, Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in schizophrenia: a meta-analysis of randomized placebo-controlled trials, Pharmacopsychiatry
Kotfis, Williams Roberson, Wilson, Dabrowski, Pun et al., COVID-19: ICU delirium management during SARS-CoV-2 pandemic
Launer, Jama, Ott, Breteler, Hoes et al., Histamine H2 blocking drugs and the risk for Alzheimer's disease: the Rotterdam study, Neurobiol. Aging
Malone, Tisdall, Fremont-Smith, Liu, Huang et al., COVID-19: famotidine, histamine, mast cells, and mechanisms
Mather, Seip, Mckay, Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19, Am. J. Gastroenterol
Meskanen, Ekelund, Laitinen, Neuvonen, Haukka et al., A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia, J. Clin. Psychopharmacol
Mukherjee, Bhattacharya, Bojkova, Mehdipour, Shin et al., Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection, J. Biol. Chem
Nasreddine, Phillips, Bedirian, Charbonneau, Whitehead et al., The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment, J. Am. Geriatr. Soc
O'mahoney, Routen, Gillies, Ekezie, Welford et al., The prevalence and long-term health effects of long Covid among hospitalised and nonhospitalised populations: a systematic review and meta-analysis
Premraj, Kannapadi, Briggs, Seal, Battaglini et al., Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis, J. Neurol. Sci
Rippin, Eldar-Finkelman, Mechanisms and therapeutic implications of GSK-3 in treating neurodegeneration, Cells
Rogers, Watson, Badenoch, Cross, Butler et al., Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives, J. Neurol. Neurosurg. Psychiatry
Rosse, Kendrick, Fay-Mccarthy, Prell, Rosenberg et al., An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy, Clin. Neuropharmacol
Shoaibi, Fortin, Weinstein, Berlin, Ryan, Comparative effectiveness of famotidine in hospitalized COVID-19 patients, Off. J. American Coll. Gastroenterol. ACG
Sun, Chen, Hu, Wu, Liang et al., Does famotidine reduce the risk of progression to severe disease, death, and intubation for COVID-19 patients? A systemic review and meta-analysis, Dig. Dis. Sci
Tenforde, Kim, Lindsell, Billig Rose, Shapiro et al., Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network -United States, MMWR Morb. Mortal. Wkly Rep
Troyer, Kohn, Hong, Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms, Brain Behav. Immun
Unal, Dokumaci, Ozkartal, Yerer, Aricioglu, Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3beta/betacatenin signaling pathway in the SH-SY5Y cell line, Chem. Biol. Interact
Varatharaj, Thomas, Ellul, Davies, Pollak et al., Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study, Lancet Psychiatry
Vindegaard, Benros, COVID-19 pandemic and mental health consequences: systematic review of the current evidence, Brain Behav. Immun
Wu, Liu, Yang, Zhang, Zhong et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm. Sin. B
Wu, Xiong, Ouk, Rabin, Herrmann et al., Gastric acid suppressants and cognitive decline in people with or without cognitive impairment, Alzheimer's & Dementia: Translat. Res. Clin. Intervent
Yamasaki, Fukuda, Tanimoto, Narahara, Kawaguchi et al., Reduction in the rate of postoperative delirium by switching from famotidine to omeprazole in Japanese hepatectomized recipients, J. Pharmaceut. Health Care Sci
Yang, George, Thompson, Silverman, Tsaava et al., Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm, Mol. Med
Yeramaneni, Doshi, Sands, Cooper, Kurbegov et al., Famotidine use is not associated with 30-day mortality: a coarsened exact match study in 7158 hospitalized patients with coronavirus disease 2019 from a large healthcare system, Gastroenterology
Zandi, Anthony, Hayden, Mehta, Mayer et al., Cache County study I: reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County study, Neurology
Zhou, Wang, Lee, Wu, Cheung et al., Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity scorematched territory-wide study, Gut
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop